KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Non-Current Deferred Tax Liability (2018 - 2026)

Bristol Myers Squibb has reported Non-Current Deferred Tax Liability over the past 15 years, most recently at $211.0 million for Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability fell 23.55% to $211.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $211.0 million through Mar 2026, down 23.55% year-over-year, with the annual reading at $222.0 million for FY2025, 95.14% down from the prior year.
  • Non-Current Deferred Tax Liability was $211.0 million for Q1 2026 at Bristol Myers Squibb, down from $222.0 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $4.9 billion in Q4 2023 and troughed at $211.0 million in Q1 2026.
  • The 5-year median for Non-Current Deferred Tax Liability is $461.0 million (2024), against an average of $1.6 billion.
  • Year-over-year, Non-Current Deferred Tax Liability surged 126.41% in 2023 and then crashed 95.14% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.2 billion in 2022, then skyrocketed by 126.41% to $4.9 billion in 2023, then decreased by 6.77% to $4.6 billion in 2024, then crashed by 95.14% to $222.0 million in 2025, then dropped by 4.95% to $211.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Non-Current Deferred Tax Liability are $211.0 million (Q1 2026), $222.0 million (Q4 2025), and $225.0 million (Q3 2025).